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The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using
published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family
members.Twenty-sevenarticlesfrom65referencesrelatedtoErbBreceptorexpressionassessmentinbladdercancerwerereviewed.
The estimates included the association signiﬁcance, hazard ratios, and 95% conﬁdence intervals (CIs) from actuarial curves
and survival analyses. A meta-analysis was done on those reports using univariate log-rank tests or a Cox-regression model.
The methods of analysis and study subjects chosen varied widely among studies. The overall risks of disease progression for
patients with EGFR or ErbB2 overexpression were 4.5 (95% CI: 2.5–8.4) and 1.1 (95% CI: 0.6–1.9), and the risks of mortality
were 3.0 (95% CI: 1.6–5.9) and 1.1 (95% CI: 1.0–1.2), respectively. However, the signiﬁcance of coexpression patterns of the ErbB
receptor family remains controversial. None of six clinical trials yielded convincing results for blockading ErbB receptor signaling
in urothelial carcinoma. The results of this analysis suggest that assessing co-expression patterns of the ErbB family may provide
better prognostic information for bladder cancer patients.
1.Introduction
One characteristic of bladder cancer is its variable patient
prognosis. About 70% of superﬁcial (Ta and T1) tumors
recur, and 10–20% of them become invasive [1]. Tumors
that are invasive at primary diagnosis carry a high risk of
progression despite radical cystectomy and other auxiliary
treatments. Conventional prognostic factors, such as tumor
stage, grade, size, and multifocality, do not accurately predict
the clinical outcome for some patients. Therefore, extensive
eﬀorts have been made to identify biomarkers for predicting
disease progression, response to treatment, and chance
of long-term survival. Currently, it is recommended that
patients with bladder cancer have regular urinary cytology,
cystoscopy, and imaging studies at followup [2].
The ErbB receptor family (also known as the epidermal
growth factor receptor (EGFR) family) is a major class of
receptor tyrosine kinase (RTK) protooncogenes. They are
important in many cell regulatory processes, such as pro-
liferation, migration, adhesion, and, potentially, cellular
transformation, including urothelial carcinogenesis. The
ErbB family consists of 4 members: ErbB1 (also called EGFR
and HER1), ErbB2 (c-erbB-2 and HER2/neu), ErbB3
(HER3), and ErbB4 (HER4). Dimerization by binding two
monomers is the regulatory mechanism for activating RTKs
[3].Insomecases,theformationofheterodimericcomplexes
allows interaction and crosstalk between diﬀerent receptors
of the same subfamily, and the ErbB receptor family is
the best example of homo- and heterodimerization in vivo
[4, 5]. Therefore, clarifying the clinical signiﬁcance of ErbB2 Advances in Urology
expression may provide important molecular targets for
cancer therapy.
EGFR signaling regulates biological processes important
for the pathogenesis of human cancers, including lung can-
cer, breast cancer, and prostate cancer [6]. In practice, ther-
apy that targets EGFR gene mutations in primary tumors has
extendedthethemeoftargetedcancertherapies[7].Inbreast
cancer, HER2 ampliﬁcation status is a pivotal biomarker in
predicting response to chemotherapy [8], and a humanized
anti-HER2 monoclonal antibody (trastuzumab) improved
the survival of HER2-positive breast cancer patients [9]. The
prognostic signiﬁcance of ErbB receptor signaling has tissue-
speciﬁc relevance. For example, EGFR/HER2-MAPK axis is
important in human breast cancer while the kinase activity
of the HER2/ErbB3 axis plays a major role in the DNA
binding and androgen receptor stability in prostate cancer
[10]. Moreover, the EGFR inhibitor geﬁtinib is ineﬀective
in treating hormone-refractory prostate cancer, a result
questioning the signiﬁcance of the EGFR/HER2 axis in the
molecular pathogenesis of prostate cancer [11].
To establish the clinical relevance of ErbB receptor family
members in bladder cancer, we systematically reviewed the
papers published in the past two decades on ErbB receptor
family expression, either one of the members or the coex-
pressionpatterns,andtheirimpactonpatientprognosis.Our
objectives were to conﬁrm the signiﬁcance of ErbB receptor
expression in predicting recurrence, progression, and mor-
tality in patients with bladder cancer, to identify factors that
mightaﬀecttheprognosticevaluationofErbBreceptors,and
toconductameta-analysisofavailableestimates.Inaddition,
we assessed the potential sources of heterogeneity underlying
the conﬂicting results, and incorporated quantitative meth-
ods to analyze the data. The updated results of clinical trials
targeting ErbB receptor signaling were also reviewed.
2.MaterialsandMethods
2.1. Search Strategy and Selection Criteria. Original articles
published between January 1985 and May 2011 showing
prognostic signiﬁcance of expression or ampliﬁcation of
ErbB receptor members in patients with bladder cancer were
systematically reviewed. Using the keywords “EGF”, “EGF-
R,” “c-erb-B1,” “c-erb-B2,” “c-erb-B3,” “c-erb-B4,” “neu,”
“epidermal growth factor,” and “bladder neoplasms or tran-
sitional cell carcinomas-in-humans,” we identiﬁed 710 rele-
vant articles in the PubMed database. The number of studies
was reduced to 65 by limiting the search to “prognosis”
or “survival,” including disease recurrence and progression.
Duplicate data, identiﬁed in the same cohort by reviewing
the interstudy similarities of investigators, source of patients,
recruitmentperiod, orinclusion criteria, wereexcluded from
the current analysis. Only the largest series were included in
our analysis.
2.2. Data Extraction, Handling, and Analyses. Our database
wasdesigned to ensurethe breadth of relevant data obtained,
based on study design, patient outcomes, tumor characteris-
tics, statistical analyses, biological samples, analytical meth-
ods (namely, immunohistochemistry [IHC], ﬂuorescence in
situ hybridization [FISH], and real-time polymerase chain
reaction [RT-PCR]), and the incidence of overexpression or
gene ampliﬁcation of ErbB receptor family members.
Two methods were used to summarize the results.
Because most articles provided only the P values or state-
ments of whether results were signiﬁcant (and no other
measures of eﬀect), the analyses of recurrence, progression,
mortality, progression-free survival, disease-free survival,
andresistancetochemotherapyandradiotherapywerebased
on deﬁnitions in the original reports. Brieﬂy, recurrence was
deﬁnedasatumorthatreappearedintheurinarybladdernot
at a higher T stage, while disease progression was deﬁned as
any tumor with a higher T stage in the local tumor, node, or
metastasis. The P values (or statements of signiﬁcance) were
extracted from association analyses (χ2 test, Fisher’s exact
test, Student’s t-test, the Mann-Whitney U-test, and logistic
regression), and the risk estimates and 95% conﬁdence
intervals (CIs) from univariate (Kaplan-Meier curves and
the log-rank test) and multivariate survival (Cox regression)
analyses. Data are summarized by providing the means of
percentages or actual numbers with either the standard
deviation (SD) or range. χ2 tests and Fisher’s exact tests
were used, when appropriate, to assess the independence of
two categorical variables. Unconditional logistic regression
models were used to identify the signiﬁcance of study
characteristics (P<0.05).
A meta-analysis using multivariate tests was then done.
Wolf’s method was used to combine the risk estimates by
applying the inverse of variance as the weighting factor.
Potential sources of heterogeneity were investigated using
graphical methods, such as the Galbraith plot. A hetero-
geneity test based on the statistics was done in all meta-
analyses. The heterogeneity was considered signiﬁcant when
P<0.10. In cases of substantial heterogeneity, random-
eﬀect models were used. The extent to which the combined
risk estimate was aﬀected by individual study was examined
by consecutively omitting every study from the meta-
analysis. Metaregression was used to explain the potential
heterogeneity from the same characteristics included in the
P value analysis. The publication bias was investigated using
Egger’s and Begg’s graphical methods. The analyses were
done using Comprehensive Meta Analysis Version 2 (Biostat,
Englewood, NJ, USA). Signiﬁcance was set at P<0.05 (two
sided).
3. Results
3.1. Signiﬁcance of Individual ErbB Receptor Expression.
Tumors recurred in 1233 patients in 16 analyses reported in
8 studies (median: 162 patients; range: 52–243) (Table 1)
[5, 12–18]. The receptor members analyzed in order of
frequency were ErbB2 (7 of 8) and EGFR (6 of 8). Three
studies[5,15,16]reportedsigniﬁcantlypositiveresults.After
data processing, only 4 reports were accepted for analysis: 2
for EGFR and 2 for ErbB2 (Figure 1(a)). The distribution of
the tumor stages in patients with cancer varied widely. All
fourstudiesusedIHCtoanalyzetheirstudysamples.Overall,
the hazard ratios of tumor recurrence were 1.588 (95% CI:
0.9–2.7).Advances in Urology 3
Table 1: Signiﬁcance of ErbB receptor family as a marker for tumor recurrence.
Study name Methods Pts no. Study subject Signiﬁcance
EGFR
[12] IHC 230 T0-1 NS
[13] IHC 73 T2–4 NS
[14] IHC 141 T0-1 NS
[15]I H C 5 2 T 0 - 1 Y e s
[16] IHC 182 T0–4 Yes
[5] IHC 245 T0–4 NS
ErbB2
[16] IHC 182 T0–4 NS
[12] IHC 230 T0-1 NS
[13] IHC 55 T2–4 NS
[14] IHC 141 T0-1 NS
[17] IHC 62 T0-1 NS
[18] IHC 248 T0-1 NS
[5] IHC 245 T0–4 Yes
ErB3
[16] IHC 128 T0–4 NS
[5] IHC 245 T0–4 Yes
ErbB4
[16] IHC 124 T0–4 NS
IHC: immunohistochemistry.
Forcancerprogression,484patientsfrom9analyseswere
reported in 8 studies (median: 60 patients; range: 21–113)
(Table 2)[ 15, 19–24]. The receptor members analyzed in
order of frequency were ErbB2 (5 of 8) and EGFR (4 of
8). Four studies [15, 19, 20, 22] found signiﬁcantly positive
results. After data processing, only 4 reports on EGFR
and 3 on ErbB2 were accepted for analysis (Figure 1(b)).
The distribution of tumor staging varied widely. All four
studies used IHC to analyze their study samples. Overall, the
hazard ratios of cancer progression were 4.611 (95% CI: 2.5–
8.4) for EGFR and 1.067 (95% CI: 0.59–1.97) and ErbB2
overexpression.
Cancer-related mortality in 3444 patients from 31 analy-
ses was reported in 20 studies (median: 88 patients, range:
39–1500) (Table 3)[ 5, 13, 15, 16, 19–27, 34–37]. The
receptormembersanalyzedinorderoffrequencywereErbB2
(18 of 20) and EGFR 8 of 20). Thirteen studies [5, 13, 15,
16, 21–23, 26, 34–37] reported signiﬁcantly positive results.
After data processing, only 3 reports on EGFR and 10 on
E rb B 2w e r ea c c e p t e df o ra n a l y s i s( Figure 2). The distribution
of tumor staging also varied widely. IHC was the most
common method of assessment; however, FISH was used in
1 study, and gene copy ampliﬁcation was used in another.
Overall, the hazard ratios of cancer death were 3.044 (95%
CI: 1.6–5.9) forEGFR and 1.090 (95% CI: 1.0–1.2) for ErbB2
overexpression.
3.2. Signiﬁcance of the Coexpression Pattern of ErbB Receptors.
T h r e es t u d i e s[ 5, 16, 28] investigated the signiﬁcance of
the coexpression patterns of ErbB receptor family members
in association with tumor recurrence and patient survival.
None of the coexpression patterns were signiﬁcant in pre-
dicting tumor recurrence. In contrast, several coexpression
patterns were independent prognostic indicators of bladder
cancer death, namely, EGFR-ErbB2, ErbB2-ErbB3 [5], and
high EGFR or ErbB2 plus low ErbB3 or ErbB4 [16, 28]
(Table 4).
3.3. Assessment and Publication Bias. A substantial funnel
plot asymmetry suggestive of the publication bias was
revealed for ErbB2 (Figure 3(b)). However, no obvious fun-
nel plot asymmetry was found for EGFR, possibly because
only 4 studies were analyzed (Figure 3(a)).
3.4. Clinical Trials of Targeting ErbB Signaling in Human
Bladder Cancer. Until February 2012, there were 6 ﬁnished
clinical trials targeting ErbB signaling in human bladder
cancer (Table 5). Cetuximab is a chimeric (mouse/human)
monoclonal antibody for blocking EGFR signaling. A phase
II clinical trial [38] of 39 pretreated patients with metastatic
urothelial carcinoma demonstrated that combined cetux-
imab and paclitaxel chemotherapy yielded a better response
rate (28.5%) than did cetuximab monotherapy, in which 9 of
11 patients had disease progression at 8 weeks.
Geﬁtinib is the ﬁrst selective inhibitor of the EGFR
tyrosine kinase domain. An overall response rate of 42.6%
(95% CI: 29.2–56.8%) was demonstrated in a phase II trial
of 58 patients with metastatic urothelial carcinoma treated
with gemcitabine and cisplatin chemotherapy plus geﬁtinib
[39, 40], the median survival time was 15.1 months (95%
CI: 11.1–21.7mo), and time to progression was 7.4 months
(95% CI: 5.6–9.2mo). Twenty-ﬁve patients completed the4 Advances in Urology
(a) Bladder cancer recurrence
(b) Bladder cancer progression (EGFR)
Figure 1: Forest plots of studies on the prognostic signiﬁcance of EGFR and ErbB2 overexpression in bladder cancer. (a) The eﬀect on
recurrence. (b) The eﬀect of EGFR (A) or ErbB2 (B) on progression. Hazard ratios and 95% (conﬁdence intervals) CIs for patients with
e i t h e rE G F R -o rE r b B 2 - p o s i t i v et u m o r s .
trial without reducing or discontinuing the geﬁtinib. The
authors concluded that this combination therapy was well
toleratedandeﬀectiveinmetastaticdisease.However,adding
geﬁtinib did not improve the response rate or patient surviv-
al. In contrast, a phase II trial of 31 pretreated patients with
metastatic urothelial carcinoma [41] reported a response
rate of 6.5%, and the authors concluded that geﬁtinib is
ineﬀective as a second-line agent for metastatic urothelial
carcinoma.
Lapatinib is an EGFR and ErbB2 dual tyrosine kinase
inhibitor.Anobjectiveresponserate(ORR)greaterthan10%
was found in only 1 of 59 patients (1.7%) in a phase II
trial using lapatinib as the second-line agent for patients
with metastatic urothelial carcinoma [42], and the diseaseAdvances in Urology 5
Table 2: Signiﬁcance of ErbB receptor family as a marker for cancer progression.
Study name Methods Pts no. Study subject Signiﬁcance
EGFR
[19] IHC 57 T0–4 Yes
[13] IHC 73 T2–4 NS
[15]I H C 5 2 T 0 - 1 Y e s
[20] IHC 113 T0–4 Yes
ErbB2
[21]F I S H 6 2 T 0 – 4 N S
[13] IHC 55 T2–4 NS
[22]I H C 3 9 T 3 - 4 Y e s
[23] IHC 21 T0-1 NS
[24] IHC 67 T2–4 NS
Table 3: Signiﬁcance of ErbB receptor family as a marker for bladder cancer death.
Study name Methods Pts no. Study subject Signiﬁcance
EGFR
[13] IHC 73 T2–4 Yes
[25] IHC 109 T2 NS
[16] IHC 182 T0–4 NS
[26] IHC 59 T2–4 Yes
[27] IHC 141 T2–4 NS
[15]
IHC 52 T0-1 NS
IHC 101 T0–4 Yes
[26]R T - P C R 5 9 T 2 – 4 Y e s
[28]R T - P C R 8 8 T 0 – 4 N S
[29] qRT-PCR 73 T0–4 NS
ErbB2
[30] Gene ampliﬁcation 163 T0–4 Yes
[31] Gene ampliﬁcation 57 T0–4 Yes
[21]F I S H 6 2 T 0 – 4 N S
[32] FISH 1500 T0–4 NS
[13] IHC 55 T2–4 NS
[22]I H C 3 9 T 3 - 4 Y e s
[25] IHC 109 T2 NS
[33] IHC 80 T2–4 NS
[16] IHC 184 T0–4 NS
[34] IHC 90 T2–4 Yes
[35] IHC 138 T2–4 Yes
[36] IHC 132 T2–4 Yes
[27] IHC 141 T2–4 NS
[37] IHC 88 T0–4 Yes
[32] IHC 1500 T0–4 NS
[5] IHC 245 T0–4 Yes
[23] IHC 89 T0–4 Yes
[28]R T - P C R 8 8 T 0 – 4 N S
[29]R T - P C R 7 3 T 0 – 4 N S
ErbB3 or ErbB4
[16] IHC 128 T0–4 NS
IHC 124 T0–4 Yes6 Advances in Urology
(a) EGFR for bladder cancer death
(b) ErbB2 for bladder cancer death
Figure 2: Forest plots of prognostic signiﬁcance of EGFR and ErbB2 overexpression on bladder cancer death. (a) EGFR. (b) ErbB2. Hazard
ratios and 95% (conﬁdence intervals) CIs for patients with either EGFR- or ErbB2-positive tumors.
was stabilized in 18 of these patients (31%). The result is
basically negative. Interestingly, the clinical advantage (ORR
and stable disease) correlated with the EGFR overexpression
(P = 0.029), and, to some extent, HER-2 overexpression.
Vandetanib is a tyrosine kinase inhibitor for EGFR, vas-
cularendothelialgrowthfactorreceptor(VEGFR),and(rear-
ranged during transfection) RET. Choueiri et al. reported
that combined vandetanib and docetaxel did not provide
more beneﬁt for ORR or patient survival than did docetaxel
plus placebo in a double-blind trial of 142 patients with
metastaticurothelialcarcinoma.Thetoxicitywasalsogreater
in the combination group [43]. Taken together, the outcome
of current clinical trials suggests that more investigations
are required to identify an appropriate strategy or a more
eﬀective agent targeting ErbB signaling in the design of
treatment for patients with urothelial carcinoma.Advances in Urology 7
Table 4: Co-expression of ErbB receptor family as a marker for bladder cancer prognosis.
Study name Methods Pts no. Study subject Signiﬁcant co-expression pattern for
Recurrence Survival
[5] IHC 245 T0–4 EGFR-ErbB2-ErbB3∗ EGFR-ErbB2
ErbB2-ErbB3
[16] IHC 184 T0–4 Not signiﬁcant High EGFR + low ErbB4
[28] RT-PCR 88 T0–4 Not done H i g hE G F R+l o wE r b B 3o rE r b B 4
High ErbB2 + low ErbB3 or ErbB4
∗P = 0.075.
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(a) EGFR for bladder cancer progression
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(b) ErbB2 for bladder cancer death
Figure 3: Funnel plots of publication bias for EGFR and ErbB2. (a) No obvious funnel plot asymmetry was found for EGFR because only
four studies were analyzed. (b) A substantial funnel plot asymmetry for ErbB2 was found, which suggests the existence of publication bias.
4. Discussion
This meta-analysis revealed that estimates of the signiﬁcance
of ErbB receptor family member expression vary substan-
tially between studies. Nonetheless, EGFR overexpression
is moderately predictive of progression and mortality in
patients with bladder cancer. ErbB2 overexpression is weakly
predictive of cancer mortality. Since relatively few studies
have examined the implications of ErbB3 and ErbB4, no
conclusioncanbemadeatthisstage.However,theseﬁndings
should be interpreted carefully because relatively few studies
were eligible for analysis.
It has been more than three decades since the discoveries
of EGF and EGFR [44, 45]. Many bladder cancer studies
examined the signaling events of this receptor family [16, 46,
47]. Given that human urine contains high concentrations
of EGF (20ng/mg creatinine) [48] and transforming growth
factor (TGF)-α (0.6ng/mg creatinine) [49], the interaction
of ligands with their cognitive receptors has been thought
crucial in the homeostasis of bladder mucosa. This hypoth-
esis is supported by clinical observations that urinary EGF
is inversely correlated with the intensity of EGFR expression
in primary tumors (P = 0.04) [47]. The ﬁnding supports
the importance of the urinary EGF and urothelial EGFR
interaction in the pathogenesis of human bladder cancer.
Whenligandsbindtotheextracellulardomainsofspecif-
ic RTKs, tyrosine kinase activity at their intracellular domain
is activated [50]. Several regulatory signaling pathways of
the ErbB receptor family are important in the prolifer-
ation, angiogenesis, migration, and metastasis of human
cancer[51].Theconventionalparadigmisthataberrantacti-
vation of ErbB receptors is generated by the overexpression
or mutations of the receptor, and by the autocrine pro-
duction of ligands [50]. It is now known that signaling
output from EGFR is quite complicated. Not only tyrosine-
phosphorylated EGFR engages at least six biochemical
downstream pathways, but EGFR family RTKs include three
other receptors, of which only ErbB4 is autonomous [52].
Other ErbB proteins may be coexpressed and activated in
the same cell, resulting in their dimerization with EGFR. The
associationofEGFRwithErbB2preventsitsdownregulation,
which reinforces the biological eﬀects of EGFR [53].
ErbB signaling may be terminated or blunted by other
mechanisms, such as the dissociation of ligands, which
causes dephosphorylation or degradation of the receptors
[54,55].Alwanetal.hypothesizedthatproteasomaltargeting
of ErbB proteins or lysosomal degradation upon ligand-
induced endocytosis is involved in EGFR downregulation
[56]. Since the ErbB receptor family has many negative
feedback mechanisms (e.g., receptor endocytosis, phospho-
rylation, and ubiquitination/deubiquitination) and crosstalk
with other pathways (such as NOTCH pathways, VEGF,
and TGF-β), components of the EGFR/ErbB network are
excellent targets for cancer therapy [57].8 Advances in Urology
Table 5: The update results of published clinical trials targeting EGFR signaling in urothelial carcinoma patients.
Study agents Pts no. ORR (%) Recommendation
EGFR signaling
Cetuximab + paclitaxel versus cetuximab 39 28.5 versus 18 The combination merits further evaluation [38]
Geftinib + Gemcitabine, cisplatin 58 42.6%
The combination of cisplatin, gemcitabine, and
geﬁtinib is well tolerated, and the addition of geﬁtinib
does not appear to improve response rate or survival
[39, 40]
Geftinib 31 6.5 Geftinib (ZD1839) is ineﬀective as a second-line agent
for urothelial carcinoma [41]
EGFR and ErbB2 signaling
Lapatinib 59 ORR (1.7%) and
SD (31%)
A negative result, but clinical beneﬁt (ORR and SD) is
correlated with EGFR overexpression (P = 0.029), and,
to some extent, HER-2 overexpression [42]
EGFR, VEGFR, and RET signaling
Vandetanib plus docetaxel versus placebo
plus docetaxel 142
ORR, 7 versus 11
(P = 0.56); PFS,
2.6m versus 1.6m
(P = 0.939); OS,
5.9m versus 7.0m
(P = 0.347)
The addition of vandetanib to docetaxel did not result
in a signiﬁcant improvement in PFS, ORR, or OS [43]
ORR: objective response rate; SD: stable disease, PFS: progression-free survival; OS: overall survival; VEGFR: vascular endothelial growth factorr e c e p t o r ;
RET: rearranged during transfection.
Several studies have reported that overexpressed or
mutant EGFR family members drive the development of
human cancers, including lung [58], breast [59], melanoma
[60], prostate [61], and urinary bladder cancer [62]. Alter-
natively, other aberrations, such as mutant forms of RAF
or PI3K, manipulate the downstream signaling in cancer
through negative feedback loops [63]. Thus, computational
charting of EGFR/ErbB signaling may guide the cell-fate
decision. Altogether, it is conceivable to speculate that assess-
ing individual ErbB family receptor expression is insuﬃcient
forestimatingthebiologicalpotentialofpatientswithcancer.
A number of studies have reported the association of
EGFR and ErbB2 overexpression with advanced stages of
bladder cancer. These phenotypes are thought to predict
patient survival, as well as the response to chemotherapy
[64, 65]. However, these biomarkers were not included as
molecular indicators for patients with bladder cancer [66,
67]. This review describes an authentic inconsistency of the
eﬃcacy of ErbB receptor expression in predicting the risk
of recurrence, progression, and mortality in patients with
bladder cancer. To some extent, this incongruity is consistent
with the discouraging results of clinical trials focusing on
blockading ErbB receptor signaling [38, 40–43].
Factors responsible for the discrepancies in this meta-
analysis include long periods of patient recruitment, a wide
range of disease statuses (T0-1, T0–4, T2–4), variability in
the immunohistochemical assays used, bias from staining
scoring,cutoﬀpoints,andsubjectivityininterpretingresults.
There are additional contributing factors, namely, the length
of followup, strategies for detecting events of interest, and
inconsistency in the inclusion of clinical and pathological
factors for multivariate analysis [68]. Not surprisingly,
diﬀerent treatment plans may have diﬀerent eﬀects on clini-
cal outcome, which might not be considered a confounding
factor [69]. The risks calculated in our meta-analysis may
be overestimated by reporting biases because hazard ratios
and 95% CIs were not described when associations were not
signiﬁcant.
5. Conclusions
In conclusion, this meta-analysis has revealed a signiﬁcant
association between ErbB family receptor expression and
progression and mortality in patients with bladder cancer
even though these ﬁndings need to be carefully interpreted.
Considering current molecular information, assessing ErbB
family coexpression patterns may provide better prognostic
information for patients with bladder cancer. Updated
clinical trials suggest that more investigations are required
to identify eﬀective agents for targeting ErbB signaling of
urothelial carcinoma. Systematic reviews and meta-analyses
are mandatory before accepting ErbB receptor expression
patterns as predictive markers for clinical application.
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